I am a
Home I AM A Search Login

Papers of the Week

2020 Mar

J Hepatol



Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial.


Brown RS, Buti M, Rodrigues L, Chulanov V, Chuang W-L, Aguilar H, Horváth G, Zuckerman E, Carrion B R, Rodriguez-Perez F, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin C-W, Zha J, Wang S, Trinh R, Mensa FJ, et al.
J Hepatol. 2020 Mar; 72(3):441-449.
PMID: 31682879.


8-week glecaprevir/pibrentasvir demonstrates high rates of sustained virological response at post-treatment week 12 (SVR12) across hepatitis C virus (HCV) genotypes (GT) 1-6 in treatment-naïve patients without cirrhosis. We evaluated glecaprevir/pibrentasvir once daily for 8 weeks in treatment-naïve patients with compensated cirrhosis.